Rep. Pete Sessions Sells Shares of AbbVie Inc. (NYSE:ABBV)

Representative Pete Sessions (Republican-Texas) recently sold shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on September 18th, the Representative disclosed that they had sold between $15,001 and $50,000 in AbbVie stock on September 14th. The trade occurred in the Representative’s “ET IRA” account.

Representative Pete Sessions also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Ares Capital (NASDAQ:ARCC) on 7/24/2026.

AbbVie Stock Performance

AbbVie stock traded up $1.11 during mid-day trading on Tuesday, reaching $265.59. The company’s stock had a trading volume of 397,568 shares, compared to its average volume of 6,534,729. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The firm’s fifty day moving average price is $255.90 and its two-hundred day moving average price is $232.37. The company has a market capitalization of $469.25 billion, a P/E ratio of 74.87, a PEG ratio of 1.19 and a beta of 0.29.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved RINVOQ (upadacitinib) for children age two and older with active polyarticular juvenile idiopathic arthritis. The expanded label adds another patient population and includes an oral solution, potentially supporting long-term growth for AbbVie’s key immunology franchise. RINVOQ European approval
• Positive Sentiment: AbbVie and Iambic announced a multiyear collaboration using Iambic’s artificial-intelligence platform to discover small-molecule therapies in immunology, neuroscience, and oncology. The deal could improve research efficiency and strengthen AbbVie’s pipeline, though financial terms and development outcomes were not disclosed. AbbVie and Iambic AI collaboration
• Positive Sentiment: Allergan Aesthetics launched AA Signature: SKIN360 in the United States, a multimodal consultation program designed to help providers address patients’ broader aesthetic goals. The initiative may support demand across AbbVie’s aesthetics portfolio and improve cross-selling, although it is unlikely to materially affect near-term earnings. Allergan Aesthetics SKIN360 launch
• Neutral Sentiment: Recent commentary remains favorable toward AbbVie as a dividend stock, citing its cash generation, dividend history, and recession-resistant pharmaceutical portfolio. Analysts and investors continue to focus on pipeline growth and performance following the company’s latest quarterly earnings beat. AbbVie versus Pfizer dividend comparison
• Negative Sentiment: With AbbVie trading close to its 52-week high and at a relatively high earnings multiple, valuation is a potential headwind. Investors may require continued earnings growth, successful pipeline execution, and strong RINVOQ performance to justify additional gains.

Analyst Ratings Changes

A number of brokerages recently issued reports on ABBV. Cantor Fitzgerald restated an “overweight” rating on shares of AbbVie in a report on Wednesday, September 16th. Piper Sandler upped their price target on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. BNP Paribas Exane boosted their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target on the stock in a report on Thursday, August 13th. Finally, UBS Group upped their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $276.64.

Hedge Funds Weigh In On AbbVie

Institutional investors have recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in AbbVie during the fourth quarter valued at approximately $5,865,055,000. Corient Private Wealth LP purchased a new stake in shares of AbbVie in the 2nd quarter worth $559,736,000. Legal & General Group Plc purchased a new position in shares of AbbVie during the second quarter valued at $2,905,952,000. Capital World Investors raised its holdings in shares of AbbVie by 106.3% in the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after acquiring an additional 6,736,161 shares in the last quarter. Finally, Jupiter Topco LLC bought a new position in AbbVie during the 2nd quarter worth about $1,560,354,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.06% of the company’s stock.

About Representative Sessions

Pete Sessions (Republican Party) is a member of the U.S. House, representing Texas’ 17th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Sessions (Republican Party) ran for re-election to the U.S. House to represent Texas’ 17th Congressional District. He won in the general election on November 5, 2024.

On October 20, 2023, Sessions announced he was running to replace Kevin McCarthy (R) as speaker of the U.S. House in the 118th Congress. Sessions lost the first round of nomination voting on October 24, 2023.

Pete Sessions was born and lives in Waco, Texas. Sessions earned a B.S. from Southwestern University in 1978. Sessions’ career experience includes working as an executive with AT&T.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.